Although both somatic TSC1 mutation [30] and mTOR mutations [31] have been reported in exceptional responders, these alterations are relatively rare in tumor types such as hormone–receptor positive breast cancer and neuroendocrine tumors, where rapalogs are commonly used. This evidence concerns the gene MTOR and neoplasm.